相关实验视频
Updated: Mar 18, 2026

07:11
Constructing Cyclic Peptides Using an On-Tether Sulfonium Center
Published on: September 28, 2022
3.2K
类作为向药物合物的多功能关键
Xue Li1, Yuechen Qian1, Jiongjia Cheng2
1Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University Nanjing 211198 China qianchu@cpu.edu.cn.
RSC medicinal chemistry
|March 16, 2026
概括
类药物合物 (PDCs) 通过使用来精确的药物输送来增强向治疗. 类发现和优化的进步旨在克服下一代精密药物的挑战.
科学领域:
- 生物化学和分子生物学
- 药理学和制药科学 药理学和制药科学
- 在瘤学瘤学.
背景情况:
- 类药物合物 (PDCs) 是一种先进的治疗药物,旨在针对药物输送.
- 他们利用来增强特异性,减少系统性毒性,治疗复杂疾病.
研究的目的:
- 审查发现,修改和优化PDCs的战略进展.
- 讨论克服临床翻译挑战和下一代PDC的未来前景.
主要方法:
- 关于药物合物的类发现和工程的当前文献的综述.
- 分析改善稳定性,组织透性和准选择性的策略.
- 探索用于控制药物释放的基于的链接剂.
主要成果:
- 类化合物作为指导装置,可以选择性地准患病细胞上过度表达的受体.
- 工程可以作为局部药物释放的酶分化的链接剂发挥作用.
- 目前的挑战包括的不稳定性,有限的组织透率和不足的准选择性.
结论:
- 基工程的战略进步对于克服PDC限制至关重要.
- 下一代PDC具有作为高效精密药物的巨大潜力.
- 需要进一步的研究才能充分实现PDCs的治疗承诺.
相关概念视频
Site-Targeted Drug Delivery Systems: Polymeric Carriers
82
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
82
Modified-Release Drug Delivery Systems: Site-Targeted
73
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
73
Peptide Bonds
85.8K
A peptide bond covalently attaches amino acids through a dehydration reaction. One amino acid's carboxyl group and another amino acid's amino group combine, releasing a water molecule. The resulting bond is the peptide bond. The products that such linkages form are peptides. As more amino acids join this growing chain, the resulting chain is a polypeptide. Each polypeptide has a free amino group at one end. This end has the N-terminal, or the amino-terminal, and the other end has a free...
85.8K
Phase II Conjugation Reactions: Overview
1.1K
Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
1.1K
Ligand Binding and Linkage
5.9K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.9K
Phase II Reactions: Sulfation and Conjugation with α-Amino Acids
1.2K
Sulfation and α-amino acid conjugation are two critical biotransformation reactions in drug metabolism. Sulfation, a phase II biotransformation reaction, involves adding a polar sulfate group to a drug, enhancing its water solubility and promoting excretion. This process can either co-occur with or occur independently of glucuronidation. Nonmicrosomal sulfotransferase enzymes catalyze the process. The reaction involves 3'-phosphoadenosine-5'-phosphosulfate or PAPS coenzyme...
1.2K

